SEC Filing Summary: Genesis Biopharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Genesis Biopharma, Inc. (not IOVANCE Biotherapeutics, Inc.) on October 4, 2012, reporting events occurring on September 30, 2012. The filing addresses the extension of maturity dates for outstanding Secured Promissory Notes.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, or margin data. The only financial metric disclosed relates to debt:
- Total Secured Promissory Notes Outstanding: $1,481,250 (issued between May and September 2012 to 13 purchasers).
- Notes Extended: All outstanding notes, including $1.1 million originally issued in May and June 2012.
Material Changes
The primary material change is the extension of the maturity date for all outstanding Secured Promissory Notes:
- Previous Maturity: September 30, 2012 (for the $1.1 million tranche) and various dates for notes issued through September.
- New Maturity: December 31, 2012.
- Terms: All other terms and conditions of the Notes remain in full force and effect.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on operations, or discussion of risks beyond the immediate debt restructuring. The extension of the maturity date implies a need for additional time to secure repayment or refinancing, though the filing does not explicitly state the company's liquidity position or future capital plans.
Key Facts for Investor Verification
- Verify the company's current ability to repay the $1,481,250 in debt by the new December 31, 2012 deadline.
- Confirm whether the extension of the notes involved any additional interest, fees, or equity conversion rights not detailed in this summary.
- Check subsequent filings to determine if the debt was repaid, refinanced, or converted to equity after December 31, 2012.
- Note the discrepancy between the requested company name (IOVANCE) and the actual filer (Genesis Biopharma).